Based on the safety profile of buparlisib with fulvestrant in the BELLE-3 trial, further studies on buparlisib with fulvestrant in postmenopausal, hormone-receptor-positive, HER2-negative, advanced breast cancer patients pretreated with endocrine treatment and mTOR inhibitors are not recommended. Here, ERBB2 is linked to breast carcinoma.